Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Follow-On Biologics Debate Creates Strange Bedfellows As Bills Emerge

Executive Summary

Sen. David Vitter's strange bedfellows might help Democrats pick up his seat in 2010, but for now, they are hoping that his unusual alliances will help them advance healthcare reform

You may also be interested in...

FTC’s Low Blow On FOBs

FTC concludes that extended brand exclusivity – or any generic exclusivity – is unnecessary for a robust follow-on biologics market.

Senate Biosimilars Bill May Create Exclusivity For Pediatrics And Extra Indications, PhRMA Says

Sponsors are committed to firm 12 years of exclusivity, but evergreening remains an obstacle to reintroduction.

Medicare Coverage For FOBs: MedPAC Weighs Least Costly Alternative, Coding Options

The Medicare Payment Advisory Commission is taking up payment issues for follow-on biologics as legislation establishing a regulatory pathway for approving such products gathers momentum in Congress.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts